---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003005"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T02:46:01.977715+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%

## Summary
- Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.
- Adjusted net loss from continuing ops $0.9M ($0.06/share); Adjusted EBITDA $0.1M; cash $53.4M, no debt.
- Updated FY2025 guidance: OEM revenue $62-65M (down 16-20%); Adj. EBITDA -3% to 3% (prev 8-10%).
- Integrity procedures on pace to more than double in 2025; over 300 surgeries in Q1; Regenerative Solutions portfolio up 33% YoY.
- Key regulatory milestones: Hyalofast second PMA module filed, MDR approved; Cingal NDA path cleared with FDA feedback.

## SEC filing metadata
- accession: 0001171843-25-003005
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325003005/0001171843-25-003005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325003005/f8k_050925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003005
- JSON: https://secwatch.observer/filing/0001171843-25-003005.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.